Thioctic Acid

(BANM, rINNM)
Thioctic Acid Chemical formula

💊 Chemical information

Acide thioctique; Acidum thiocticum; Alpha Lipoic Acid; Kwas tioktynowy; Kyselina thioktová; Lipoic Acid; tico, ácido. 5-(1,2-Dithiolan-3-yl)valeric acid.
Chemical formula: C8H14O2S2 = 206.3.
CAS — 62-46-4.
ATC — A16AX01.
ATC Vet — QA16AX01.

Pharmacopoeias.

In Eur. and US.

Ph. Eur. 6.2

(Thioctic Acid). A yellow, crystalline powder. M.p. about 61°. Very slightly soluble in water; very soluble in dimethylformamide; freely soluble in methyl alcohol. Protect from light.

USP 31

(Alpha Lipoic Acid). M.p. 60.0° to 62.0°.

💊 Profile

Thioctic acid is used for its antoxidant effects in the treatment of diabetic neuropathy. It has been tried in the treatment of liver dysfunction and in subacute necrotising encephalopathy. Beneficial results have been claimed in amanitin poisoning after ingestion of the mushroom Amanita phalloides, but such use is controversial. Ethylenediamine thioctate, sodium thioctate, thioctic acid amide (thioctamide), and trometamol thioctate have been used similarly.

Diabetic neuropathy.

References1-5 to the benefits of thioctic acid in diabetic neuropathy.
1. Ziegler D, et al. Effects of treatment with the antioxidant α-lipoic acid on cardiac autonomic neuropathy in NIDDM patients: a 4month randomized controlled multicenter trial (DEKAN study). Diabetes Care 1997; 20: 369–73
2. Ziegler D, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III study). Diabetes Care 1999; 22: 1296–1301
3. Ametov AS, et al. The sensory symptoms of diabetic polyneuropathy are improved with α-lipoic acid: the SYDNEY trial. Diabetes Care 2003; 26: 770–6. Correction. ibid.; 2227
4. Ziegler D, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a meta-analysis. Diabet Med 2004; 21: 114–21
5. Ziegler D, et al. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006; 29: 2365–70.

Pharmacokinetics.

References.
1. Teichert J, et al. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease. J Clin Pharmacol 2005; 45: 313–28.

💊 Preparations

USP 31: Alpha Lipoic Acid Capsules; Alpha Lipoic Acid Tablets.

Proprietary Preparations

Arg.: Biletan; Ciagen; Neurotioct; Neutracol; Sigmus; Tioctan; Austria: Thioctacid; Tioctan; Cz.: Alpha-Lipon†; Thioctacid; Thiogamma; Ger.: AlphaLipogamma; Alpha-Lipon; alpha-Vibolex; Alphaflam; Azulipont†; Biomolipon; duralipon; espa-lipon†; Fenint†; Juthiac†; Neurium; Pleomix-Alpha†; Thioctacid; Thiogamma; Tromlipon; Verla-Lipon; Vitatrans; Hung.: Thioctacid; Thiogamma; Indon.: Alanox; Mecola Forte; Ital.: Tiobec Crema; Jpn: Tioctan†; Mex.: Thioctacid; Pol.: Neurex; Thiogamma; Rus.: Berlithion (Берлитион); Espa-Lipon (Эспа-липон); Thioctacid (Тиоктацид); Thiogamma (Тиогамма); Thai.: Lipoicin†. Multi-ingredient: Arg.: Biletan Enzimatico; Carbogasol Digestivo; Co-Tioctan; Nervomax TB12; Canad.: Biotrim†; Hong Kong: Lipochol; India: Alcrin-M; Indon.: Alicron; Aptivium Liver Support; Mecola; Reliv; Ital.: Alfa Lip; Angiovein; Byodinoral; Depatox; Lipoacid Combi; Neuralfa; Neuroptic; Osteolip; Tiobec; Tiofort; Philipp.: Illumina; Port.: Lipoacid; Lipoacid Combi†; Spain: Policolinosil; Thai.: Lipochol.
Published May 08, 2019.